Drug · CHEMBL682
AMODIAQUINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMODIAQUINE. Drugs and targets, record CHEMBL682. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL682
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Amodiaquin, Amodiaquina, Amodiaquinum, GNF-Pf-5648, NSC-13453, SJ000110703, Sunoquine
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| malaria | Approval | ATC and TTD | 51 | 48 | https://conductscience.org/library/drugs?q=MONDO_0005136 |
| Plasmodium falciparum malaria | Phase 3 | ClinicalTrials.gov | 13 | 13 | https://conductscience.org/library/drugs?q=MONDO_0005920 |
| Plasmodium vivax malaria | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005921 |
| Fever | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0001945 |
| schistosomiasis | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0015254 |
Source Open Targets
Trials128
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03143218 | Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) | Phase 3 | 5,920 | 2022-01-28 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT04319380 | Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study | Phase 3 | 5,098 | 2024-09-20 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT00297882 | Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon | Phase 3 | 816 | 2021-06-08 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT00852371 | Intermittent Preventive Treatment of Malaria in Schoolchildren | Phase 3 | 780 | 2024-03-21 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT03355664 | Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam | Phase 3 | 310 | 2022-07-15 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT03178643 | Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) | Phase 4 | 246 | 2024-03-27 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT04532931 | Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 | Phase 2 | 192 | 2025-07-28 | artesunate-amodiaquine | A combination that names it | ClinicalTrials.gov |
| NCT02851108 | Methylene Blue Against Falciparum Malaria in Burkina Faso | Phase 2 | 100 | 2020-03-25 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT01955382 | Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria | Phase 2 | 70 | 2018-02-06 | amodiaquine | Its name | ClinicalTrials.gov |
| NCT00712374 | Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal | Phase 4 | 100,000 | amodiaquine | Its name | ClinicalTrials.gov |
1 to 10 of 128
See all 128 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 1 Artemether-Lumefantrine vs 2 Amodiaquine-Artesunate: Cure Rate Day 14 | 192 of 204 | 563 of 612 | 816 | NCT00297882 | Trial comparisons |
| 1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): deaths from any cause | 2 of 204 | 2 of 612 | 816 | NCT00297882 | Trial comparisons |
| 1 Artemether-Lumefantrine AL vs 2 Amodiaquine-Artesunate AQ-AS: Cure Rate on Day 28 | 197 of 204 | 603 of 612 | 816 | NCT00297882 | Trial comparisons |
| 1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): serious adverse events | 6 of 204 | 3 of 612 | 816 | NCT00297882 | Trial comparisons |
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm | 146 of 154 | 151 of 156 | 310 | NCT03355664 | Trial comparisons |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Number of Severe Adverse Events by Study Arm | 2 of 154 | 5 of 156 | 310 | NCT03355664 | Trial comparisons |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: deaths from any cause | 0 of 154 | 0 of 156 | 310 | NCT03355664 | Trial comparisons |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: serious adverse events | 2 of 154 | 5 of 156 | 310 | NCT03355664 | Trial comparisons |
| AS-AQ-MB vs AS-AQ-PQ: serious adverse events | 2 of 50 | 0 of 50 | 100 | NCT02851108 | Trial comparisons |
| AS + oAC vs AS Only (Water): Safety | 35 of 35 | 35 of 35 | 70 | NCT01955382 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials110
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL682
GET https://conductscience.org/api/drugs/v1/CHEMBL682/trials?page=2